MedPath

FRESENIUS KABI USA, LLC

FRESENIUS KABI USA, LLC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

401

FDA:400
NMPA:1

Drug Approvals

Methocarbamol Injection

Product Name
美索巴莫注射液
Approval Number
国药准字HJ20240009
Approval Date
Apr 17, 2024
NMPA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

First Posted Date
2014-03-13
Last Posted Date
2014-03-13
Lead Sponsor
Fresenius Kabi USA, LLC
Target Recruit Count
32
Registration Number
NCT02086227
Locations
🇺🇸

West Houston Clinical Research Services, 2026 Wirt Road, Houston, Texas, United States

News

Smart Drug Delivery Systems Market Poised for 17% Growth as Chronic Disease Management Evolves

The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.

© Copyright 2025. All Rights Reserved by MedPath